$3.36-0.04 (-1.18%)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
SAB Biotherapeutics, Inc. in the Healthcare sector is trading at $3.36. Wall Street consensus targets $10.10 (10 analysts), implying a +200.6% move over the next 12 months. The stock is currently 49% below its 52-week high of $6.60, remaining 2.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candi...
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Emergent BioSolutions Inc. (NYSE:EBS) is one of the best pharmaceutical stocks to invest in. TheFly reported on April 30 that EBS announced that Singapore’s Health Sciences Authority approved an expanded use of ACAM2000, allowing its use in preventing mpox […]
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, SAB Biotherapeutics...
SAB Biotherapeutics Inc (SABS) reports significant progress in its SAB142 program despite increased R&D and G&A expenses, maintaining a strong cash position to support future growth.
SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider first-quarter loss alongside higher research and development spending. Chief Executive Officer Sa
SAB Biotherapeutics (NASDAQ:SABS) used an appearance at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to outline its strategy in type 1 diabetes (T1D), emphasizing development of a fully human anti-thymocyte globulin (ATG) designed to preserve pancreatic beta cell function in newly d